ISSN: 2155-9597
Journal of Bacteriology & Parasitology

OPEN ACCESS Freely available online

Perspective

The Emergence of Bacteria in Non-Oncological Drug Delivery

Yan Liu*

Department of Cardiology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

DESCRIPTION

In the field of modern medicine, the search for innovative drug delivery systems has led researchers to explore unconventional avenues. One such area gaining traction is bacteria-based drug delivery, which holds immense potential for treating a quantities of non-oncological diseases. Utilising the unique attributes of bacteria, scientists are developing new approaches to deliver therapeutics with precision, efficacy, and reduced side effects. This article focus into the emerging field of bacteria-based drug delivery, exploring its potential applications, mechanisms, challenges, and future prospects in the treatment of non-oncological diseases.

Advantages as drug delivery vehicles

Bacteria, long regarded as pathogens, are now being regulated as allies in the fight against disease. Engineered bacteria offer several advantages as drug delivery vehicles:

Targeting abilities: Bacteria can be engineered to target specific tissues or cell types within the body, allowing for precise drug delivery to disease sites while minimizing off-target effects.

Self-propulsion: Certain bacteria possess motility mechanisms, enabling them to navigate through complex biological environments and reach target locations more efficiently.

Payload capacity: Bacteria have the inherent ability to carry and deliver therapeutic payloads, including proteins, nucleic acids, and small molecules, offering versatility in drug delivery applications.

Biofilm formation: Some bacteria can form biofilms on surfaces, providing a protective environment for sustained drug release and prolonged therapeutic effects.

Applications of bacteria-based drug delivery

The potential applications of bacteria-based drug delivery extend across a wide spectrum of non-oncological diseases, including infectious diseases, inflammatory disorders, metabolic disorders, and neurological conditions. Engineered bacteria can be used to deliver antimicrobial agents directly to infectious sites, overcoming bacterial resistance mechanisms and enhancing treatment efficacy. Bacteria can be programmed to produce anti-inflammatory cytokines or immunomodulatory molecules, providing focused treatment for inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease. Engineered bacteria hold potential for delivering therapeutic enzymes or metabolic regulators to treat metabolic disorders such as diabetes, obesity, and metabolic syndrome. Bacteria-based drug delivery systems can be altered to target the central nervous system, enabling the delivery of neuroprotective agents or gene therapies for neurological disorders like Alzheimer's disease and Parkinson's disease.

Mechanisms of bacteria-mediated drug delivery

Bacteria employ various mechanisms to deliver therapeutic payloads to target cells or tissues such as surface display, secretion systems, tumor targeting. Therapeutic proteins or peptides can be displayed on the surface of bacteria using genetic engineering techniques, allowing for direct interaction with target cells or receptors. Bacteria possess secretion systems that enable the export of proteins or molecules into the extracellular environment or directly into target cells, facilitating drug delivery. Engineered bacteria can exploit the unique microenvironment of tumors to selectively target cancer cells, delivering cytotoxic agents or immunotherapies with precision.

Despite its potential, bacteria-based drug delivery faces several challenges and considerations: safety concerns, controllability, immune response, regulatory hurdles. The use of live bacteria as drug delivery vehicles raises safety concerns regarding potential pathogenicity, immunogenicity, and unintended effects on host microbiota. Achieving precise control over bacterial behavior, localization, and payload release remains a significant challenge, requiring sophisticated engineering strategies. Host immune responses to engineered bacteria may limit their therapeutic efficacy and pose risks of adverse reactions, necessitating strategies to evade immune detection or modulation. The development and approval of bacteria-based drug delivery

Correspondence to: Yan Liu, Department of Cardiology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, E-mail: yanliu@hotmail.com

Received: 02-Jan-2024, Manuscript No. JBP-24-25013; **Editor assigned:** 05-Jan-2024, Pre QC No. JBP-24-25013 (PQ); **Reviewed:** 19-Jan-2024, QC No. JBP-24-25013; **Revised:** 26-Jan-2024, Manuscript No. JBP-24-25013 (R); **Published:** 02-Feb-2024, DOI: 10.35248/2155-9597.24.15.496

Citation: Liu Y (2024) The Emergence of Bacteria in Non-Oncological Drug Delivery. J Bacteriol Parasitol. 15:496.

Copyright: © 2024 Liu Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

systems require adherence to rigorous regulatory standards, including safety, efficacy, and manufacturing considerations.

Despite the challenges, the field of bacteria-based drug delivery holds immense promise for revolutionizing the treatment of non-oncological diseases. Future research efforts will focus on engineering advancements, immunomodulation strategies, clinical translation, and multidisciplinary collaboration. Continued advancements in genetic engineering, synthetic biology, and nanotechnology will enable the development of safer, more controllable bacteria-based drug delivery systems. Strategies to modulate host immune responses and minimize immunogenicity will enhance the therapeutic potential of engineered bacteria. Translation of preclinical findings into clinical trials and eventual commercialization will be important for realizing the clinical impact of bacteria-based drug delivery. Collaboration between scientists, engineers, clinicians, and regulatory agencies will be essential for addressing the multifaceted challenges and accelerating the translation of bacteria-based drug delivery technologies into clinical practice.

CONCLUSION

Bacteria based drug delivery represents an ideal approach in the field of drug delivery, offering novel strategies for treating non-oncological diseases with precision and efficacy. By regulating the unique capabilities of bacteria, researchers are supposed to overcome longstanding challenges in drug delivery and result in a new era of personalized medicine. With continued innovation, collaboration, and translation efforts, bacteria-based drug delivery has the potential to transform the landscape of modern healthcare and improve patient outcomes across diverse disease areas.